Financings in Brief: Somnus Medical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Somnus Medical Technologies: Plans for an initial public offering by Somnus are outlined in a preliminary prospectus filed with the Securities and Exchange Commission Sept. 11. The number of shares to be included in the offering and the price per share are yet to be determined but the filing values the IPO at up to $46 mil. A portion of the proceeds would be used to develop Somnus' domestic sales and marketing capabilities following the U.S. launch in July of the firm's first product, its Somnoplasty radiofrequency ablation system for treatment of snoring via reduction of soft tissue ("The Gray Sheet" Aug. 4, I&W-4).